Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies

CONCLUSION: IS is prognostic in stage III CRC treated with FOLFOX or CAPOX, including within clinically relevant tumor subgroups. Possible variation in IS prognostic value by age and MMR status, and prediction of benefit from extended adjuvant therapy merit validation.PMID:38484206 | DOI:10.1200/JCO.23.01648

Source: Clinical Colorectal Cancer - March 14, 2024 Category: Cancer & Oncology Authors: Enric Domingo Caroline Kelly Jennifer Hay Owen Sansom Noori Maka Karin Oien Tim Iveson Mark Saunders Rachel Kerr Ian Tomlinson Joanne Edwards Andrea Harkin Marta Nowak Viktor Koelzer Alistair Easton Ioannis Boukovinas Eleni Moustou Ippokratis Messaritakis Source Type: research